Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023

Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024

Published:2024-08 Issue:8 Volume:18 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Antunes Liliana¹^ORCID,Mazagatos Clara²³^ORCID,Martínez‐Baz Iván³⁴^ORCID,Naesens Reinout⁵^ORCID,Borg Maria‐Louise⁶,Petrović Goranka⁷^ORCID,Fatukasi Terra⁸^ORCID,Jancoriene Ligita⁹^ORCID,Machado Ausenda¹⁰^ORCID,Oroszi Beatrix¹¹^ORCID,Husa Petr¹²^ORCID,Lazar Mihaela¹³^ORCID,Dürrwald Ralf¹⁴^ORCID,Howard Jennifer¹^ORCID,Melo Aryse¹⁵^ORCID,Pérez‐Gimeno Gloria²³^ORCID,Castilla Jesús³⁴^ORCID,Bernaert Eva⁵,Džiugytė Aušra⁶^ORCID,Makarić Zvjezdana Lovrić⁷^ORCID,Fitzgerald Margaret⁸^ORCID,Mickienė Auksė¹⁶,Gomez Verónica¹⁰^ORCID,Túri Gergő¹¹^ORCID,Součková Lenka¹²^ORCID,Marin Alexandru¹⁷^ORCID,Tolksdorf Kristin¹⁸^ORCID,Nicolay Nathalie¹⁹^ORCID,Rose Angela M. C.¹^ORCID,

Affiliation:

1. Epidemiology Department Epiconcept Paris France

2. National Centre for Epidemiology Institute of Health Carlos III Madrid Spain

3. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) Madrid Spain

4. Instituto de Salud Pública de Navarra – IdiSNA Pamplona Spain

5. Department of Medical Microbiology and Infection Prevention & Control Ziekenhuisnetwerk Antwerpen Antwerp Belgium

6. Infectious Disease Prevention and Control Unit (IDCU) Health Promotion and Disease Prevention Msida Malta

7. Croatian Institute of Public Health Zagreb Croatia

8. Health Service Executive‐Health Protection Surveillance Centre (HPSC) Dublin Ireland

9. Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty Vilnius University Vilnius Lithuania

10. Epidemiology Department National Health Institute Doutor Ricardo Jorge Lisbon Portugal

11. National Laboratory for Health Security, Epidemiology and Surveillance Centre Semmelweis University Budapest Hungary

12. University Hospital Brno Masaryk University Brno Czechia

13. Cantacuzino National Military‐Medical Institute for Research and Development Bucharest Romania

14. National Reference Centre for Influenza Robert Koch Institute Berlin Germany

15. Infectious Diseases Department National Health Institute Doutor Ricardo Jorge Lisbon Portugal

16. Department of Infectious Diseases Lithuanian University of Health Sciences Kaunas Lithuania

17. Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases Bucharest Romania

18. Department for Infectious Disease Epidemiology Robert Koch Institute Berlin Germany

19. European Centre for Disease Prevention and Control Stockholm Sweden

Abstract

ABSTRACTWe conducted a multicentre test‐negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID‐19 vaccines against PCR‐confirmed SARS‐CoV‐2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID‐19 vaccines conferred protection against COVID‐19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.

Funder

European Centre for Disease Prevention and Control

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.13360

Reference13 articles.

1. European Medicines Agency “COVID‐19 Medicines ”https://www.ema.europa.eu/en/human‐regulatory‐overview/public‐health‐threats/coronavirus‐disease‐covid‐19/covid‐19‐medicines.

2. European Centre for Disease Prevention and Control (ECDC) “Interim COVID‐19 Vaccination Coverage in the EU/EEA During the 2023–24 Season Campaigns ” (2024) ECDC Stockholm 2024 https://www.ecdc.europa.eu/en/publications‐data/interim‐covid‐19‐vaccination‐coverage‐eueea‐during‐2023‐24‐season‐campaigns.

3. European Centre for Disease Prevention and Control (ECDC) “Communicable Disease Threats Report 17–23 December 2023 Week 51 ” (2023) ECDC Stockholm 2024 https://www.ecdc.europa.eu/en/publications‐data/communicable‐disease‐threats‐report‐17‐23‐december‐2023‐week‐51.

4. European Centre for Disease Prevention and Control (ECDC) “Core Protocol for ECDC Studies of COVID‐19 Vaccine Effectiveness Against Hospitalisation With Severe Acute Respiratory Infection Laboratory‐Confirmed With SARS‐CoV‐2 or With Seasonal Influenza—Version 3.0 ” (2024) ECDC Stockholm 2024 https://www.ecdc.europa.eu/en/publications‐data/core‐protocol‐ecdc‐studies‐covid‐19‐vaccine‐effectiveness‐3.